BRIEF-Waystar Is Close To Acquiring Iodine Software, A Private-Equity Backed Company, For Over $1.2 Billion-WSJ-March 2024-www.financetom.com

BRIEF-Waystar Is Close To Acquiring Iodine Software, A Private-Equity Backed Company, For Over $1.2 Billion-WSJ

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Waystar Is Close To Acquiring Iodine Software, A Private-Equity Backed Company, For Over $1.2 Billion-WSJ

Jul 23, 2025 1:36 PM

July 23 (Reuters) - Waystar Holding Corp ( WAY ):

* WAYSTAR IS CLOSE TO ACQUIRING IODINE SOFTWARE, A

PRIVATE-EQUITY

BACKED COMPANY, FOR OVER $1.2 BILLION-WSJ

Source text: https://tinyurl.com/32efb8mu

Further company coverage:

Previous page： Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis Next page： Pharming Reports Positive Phase III Data on Leniolisib in Children With Rare Primary Immunodeficiency; Shares Rise

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis

Dec 11, 2024

11:02 AM EST, 12/11/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients. The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary...

Pharming Reports Positive Phase III Data on Leniolisib in Children With Rare Primary Immunodeficiency; Shares Rise

Dec 11, 2024

11:00 AM EST, 12/11/2024 (MT Newswires) -- Pharming Group ( PHAR ) reported Wednesday positive phase III data for its investigational drug leniolisib in children aged between four and 11 years with activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency. The biopharmaceutical company said the data was consistent with improvements seen in a previously reported randomized controlled trial in...

REUTERS NEXT-US bank executives expect Trump to ease rules, fuel growth

Dec 11, 2024

NEW YORK (Reuters) - President-elect Donald Trump is expected to adopt pro-growth policies that ease U.S. banking and credit card regulations, while spurring deals, industry executives said on a panel at the Reuters NEXT conference in New York on Wednesday. I hope the new administration will use this as a point to do a reset, Barclays U.S. consumer Bank CEO Denny Nealon...

BRIEF-Hershey's Main Owner Hershey Trust Rejects Mondelez's Offer As Too Low - Bloomberg News

Dec 11, 2024

Dec 11 (Reuters) - * HERSHEY'S MAIN OWNER HERSHEY TRUST REJECTS MONDELEZ'S OFFER AS TOO LOW - BLOOMBERG NEWS Source text: https://tinyurl.com/2accxuko ...